September 30, 2016 / 11:27 AM / 10 months ago

BRIEF-Regeneron announces phase 2 study of aflibercept

1 Min Read

Sept 30 (Reuters) - Regeneron Pharmaceuticals Inc :

* Formulated with rinucumab (anti-PDGFR-beta) shows no benefit over aflibercept alone in neovascular age-related macular degeneration

* Combination therapy did not demonstrate improvement in BCVA versus intravitreal aflibercept injection monotherapy at 12 weeks

* Adding rinucumab to aflibercept showed no benefit on anatomic endpoints Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below